Chairman, President, & CEO
Mr. Dahlhauser has more than 25 years of experience in the commercial application of molecular technologies. He has served as Insight Genetics’ Chairman and CEO since the formation of the company in 2007 and was previously the Chairman and CEO of Genetic Assays, Inc., a molecular clinical diagnostics company. Dahlhauser has been a Certified Public Accountant since 1986.
Dr. Hout received his Ph.D. in molecular virology and continued his training at Vanderbilt as a postdoctoral fellow in biochemistry. Dr. Hout has more than 15 years of assay development and design throughout his tenure. During his time at Insight Genetics, Dr. Hout has published extensively on the development, validation, and performance of both qPCR and Next Generation sequencing clinical assays presenting numerous posters and presentations at national meetings. He is also board certified in the state of TN as a licensed Laboratory Supervisor and has extensive experience with both CLIA and CAP guidelines and compliance. Dr. Hout maintains and manages close relationships with numerous pharmaceutical companies and other diagnostic companies to create a company that can fulfill a wide range of molecular assay development and testing needs including a variety of other diagnostic services.
Chief Technology Officer
Rob Seitz is a seasoned molecular diagnostics professional with extensive experience in business strategy and product development and expertise in lung cancer and breast cancer. Rob was Senior Vice President for Technology Assessment at Clarient, Inc. He also served as CEO and co-founder of Applied Genomics, Inc. (AGI) prior to its acquisition by Clarient. Rob earned his B.S. in chemistry from the University of South Alabama and obtained a M.Div. at Fuller Theological Seminary.
Scientific Founder & Chief Scientific Officer
Dr. Morris is an internationally recognized physician-scientist and translational investigator whose work focuses on molecular oncology. He was most recently a clinician and researcher at St. Jude Children’s Research Hospital, where his laboratory discovered and characterized a number of oncogenes including NPM-ALK and several other ALK fusion genes. He earned his MD from Louisiana State University, completed an internal medicine residency at the University of Texas Southwestern Health Science Center, and trained in medical oncology at Yale University School of Medicine.
Chief Strategic Adviser
Dr. Chen has broad research and development and merchant banking experience in the life science industry. Before founding Ignatius Transaction Partners, he was a managing director at Burrill & Company. Prior to banking, he led R&D at Roche Diagnostics, Novartis and start-up companies. He received his academic training at the University of Wisconsin and Stanford University.